#1 Clinical Trials Search in Europe

Non-small cell lung cancer stage II – Trials in Disease

Go back

Ongoing Clinical Trials for Non-Small Cell Lung Cancer Stage III

This article provides comprehensive information about 27 ongoing clinical trials investigating new treatments for non-small cell lung cancer stage III. These studies are testing various immunotherapy drugs, targeted therapies, and treatment combinations across multiple European countries to improve outcomes for patients with this locally advanced form of lung cancer.

Clinical trial locations

Study for Patients with Lung or Urinary Tract Cancer Continuing Treatment with Durvalumab, Infliximab, and Mycophenolate Mofetil

This trial is designed for patients who are already benefiting from durvalumab treatment in a previous cancer study. The main requirement is that participants must have provided informed consent and be eligible to continue receiving durvalumab at a fixed dose of 1500 mg every four weeks.

Patients who have other types of cancer not included in the study, those who haven’t completed required previous treatments, individuals with medical conditions interfering with the study treatment, those unable to follow procedures, pregnant or breastfeeding women, people with severe allergies to study medications, those with serious infections, current participants in other trials, people with substance abuse history, and those who recently had major surgery cannot participate.

The study focuses on providing continued treatment with durvalumab for patients with locally advanced non-small cell lung cancer that cannot be surgically removed. The medication works by helping the immune system fight cancer cells. During the trial, participants will be monitored for safety and tolerability, with serious adverse events tracked for up to 90 days after the last treatment dose.

The investigational drug being used is durvalumab, an immunotherapy medication administered through intravenous infusion. It blocks specific proteins that prevent immune system attacks on cancer cells, allowing better recognition and destruction of tumors.

Study of accelerated chemoradiotherapy followed by durvalumab treatment in patients with locally advanced non-small-cell lung cancer (NSCLC) using PET imaging guidance

This German study evaluates whether using FDG-PET imaging to guide faster radiation treatment combined with chemotherapy and durvalumab immunotherapy works as well as standard treatment for patients with stage III non-small cell lung cancer that cannot be surgically removed and has PD-L1 expression of at least 1%.

To participate, patients must have adequate blood counts (hemoglobin at least 9.0 g/dL, white blood cells above 1.5 × 10⁹/L, platelets above 100 × 10⁹/L), normal liver and kidney function, weigh more than 30 kg, be at least 18 years old, have good lung function test results, and agree to use effective birth control. They must also be able to undergo combined chemotherapy and radiation therapy followed by immunotherapy, with an ECOG performance status of 0 or 1.

Excluded patients include those with small cell lung cancer history, previous chest radiation therapy, PD-L1 expression below 1%, metastatic disease, serious heart conditions or uncontrolled high blood pressure, active autoimmune disease requiring treatment, current immunosuppressive medications, uncontrolled infections, recent trial participation, pregnancy or breastfeeding, known allergies to study medications, conditions making chemotherapy/radiation unsafe, inability to undergo FDG-PET scanning, and mental conditions affecting study compliance.

The trial tests durvalumab, an immunotherapy medication that blocks proteins allowing cancer cells to hide from the immune system, combined with chemoradiotherapy where chemotherapy makes cancer cells more sensitive to radiation treatment. FDG-PET scanning uses radioactive tracers to identify cancer cell locations for treatment planning.

Study of IPH5201 and Durvalumab for Pre- and Post-Surgery Treatment in Patients with Early-Stage Non-Small Cell Lung Cancer

This trial in Poland, Hungary, Greece, and France studies IPH5201 and durvalumab as treatments given before and after surgery for early-stage non-small cell lung cancer. Patients must be at least 18 years old with newly diagnosed NSCLC (stages IIA to IIIA) that can be surgically removed through lobectomy, sleeve resection, or bilobectomy. They need WHO/ECOG Performance Status of 0-1, adequate organ and bone marrow function, life expectancy of at least 12 weeks, weigh more than 35 kg, and provide tumor samples for testing specific markers.

Patients with other cancer types, those outside the specified age range, those unable to safely undergo surgery, those with serious interfering health conditions, pregnant or breastfeeding women, those who recently received certain treatments, and those unable to follow study procedures are excluded.

The trial aims to evaluate treatment effectiveness and safety in reducing cancer. Both medications are administered intravenously. The study will assess whether treatments can achieve complete response (no cancer cells found after surgery) and monitor disease-free periods. IPH5201 is experimental, targeting proteins involved in tumor growth to enhance immune response, while durvalumab blocks proteins preventing immune system attacks on cancer cells.

Study of Volrustomig and Drug Combination for Patients with Early-stage Resectable Non-small Cell Lung Cancer

This study across Belgium, Hungary, Italy, France, Portugal, Spain, and Ireland tests multiple medications for early-stage resectable non-small cell lung cancer, including volrustomig, carboplatin, falbikitug, paclitaxel, datopotamab deruxtecan, cisplatin, durvalumab, oleclumab, and monalizumab, all administered intravenously.

Eligible patients must have newly diagnosed NSCLC (stages IIA to IIIB) that can be surgically removed, WHO/ECOG performance status of 0 or 1, adequate organ and bone marrow function, adequate lung function, and provide tumor samples for testing PD-L1, EGFR, or ALK markers.

Excluded patients include those with other cancer types, lung cancer not in early stages (II to IIIB), non-resectable cancer, those who received previous treatments, those with serious health conditions, pregnant or breastfeeding women, and those unable to follow study procedures.

The study evaluates treatments given before surgery (neoadjuvant) to shrink tumors and after surgery (adjuvant) to eliminate remaining cancer cells and reduce recurrence risk. The medications work through various mechanisms including immune system enhancement and targeting specific proteins involved in cancer growth.

Study on Sotorasib for Patients with Advanced KRAS G12C-Mutated Non-Small Cell Lung Cancer and Comorbidities

This trial in Norway, Denmark, and Sweden studies sotorasib for KRAS G12C-mutated non-small cell lung cancer. Patients must have adequate bone marrow and organ function, mean resting corrected QT interval below specific limits, be over 18 years old, have confirmed NSCLC stage III or IV that cannot be cured, documented KRAS G12C mutation, have received at least one previous treatment including checkpoint inhibitor, ECOG status 0-2, life expectancy at least 12 weeks, at least one measurable tumor, and meet pregnancy test requirements for women.

Patients without KRAS G12C-mutated NSCLC, those outside the specified age range, and vulnerable populations (who are not excluded) cannot participate. Both male and female patients are eligible.

Sotorasib is an enzyme inhibitor taken as an oral tablet designed to reduce tumor size by blocking proteins that help cancer cells grow. The study will monitor tumor size changes, overall health, disease progression time, treatment response duration, and safety through various assessments.

Study on Sotorasib for Patients with Unresectable Stage III Non-Small Cell Lung Cancer with KRAS Mutation

This Spanish trial evaluates sotorasib for unresectable stage III NSCLC with KRAS p.G12C mutation. Patients must be at least 18 years old, have ECOG performance status 0-1, confirmed diagnosis of unresectable stage III NSCLC, received radiotherapy before joining (with recovery from side effects except hair loss), confirmed KRAS p.G12C mutation, life expectancy at least 12 weeks, mandatory baseline PET-CT scan, mediastinal adenopathies confirmed by tissue test, brain CT or MRI scan, at least one measurable lesion, adequate blood and organ function, written informed consent, and agreement to use effective birth control.

The trial uses sotorasib (LUMYKRAS 120 mg film-coated tablets) given orally. The study aims to assess effectiveness in treating this specific lung cancer mutation type by monitoring progression-free survival at 12 months, along with overall response rate and survival. Sotorasib works by targeting and inhibiting the KRAS p.G12C protein involved in cancer cell growth and survival.

Study on the Effects of Adding Durvalumab After Chemotherapy and Surgery in Patients with Resectable Non-Small Cell Lung Cancer

This trial across Estonia, Italy, France, Austria, Belgium, Ireland, and Netherlands studies adding durvalumab after initial treatment in patients with early-stage operable NSCLC. The treatment combines chemotherapy and durvalumab before surgery (neoadjuvant treatment), followed by surgery and continued durvalumab afterward (adjuvant treatment).

Eligible patients must have confirmed NSCLC, resectable and operable primary tumor, adequate organ function, fitness for platinum-based chemotherapy, known PD-L1 status without EGFR or ALK mutations, normal blood/kidney/liver function, ECOG performance status 0-1, at least 18 years old, weighing more than 30 kg, and life expectancy at least 12 weeks.

The medications used include cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel (chemotherapy drugs) plus durvalumab (immunotherapy), all administered through intravenous infusion. The goal is to determine if adding durvalumab after initial treatment can prevent cancer recurrence.

Study on the Safety and Effectiveness of BNT327 with Chemotherapy for Patients with Non-Small Cell Lung Cancer

This trial in Germany, Poland, Italy, Romania, Spain, France, and Belgium investigates BNT327 combined with chemotherapy for non-small cell lung cancer. The study has two phases: Phase II assesses safety and tolerability of BNT327 at different doses with chemotherapy, while Phase III compares BNT327 combined with chemotherapy to pembrolizumab and chemotherapy.

Eligible patients must provide informed consent, use effective birth control, be willing to attend scheduled visits, be at least 18 years old, have confirmed Stage IIIB/IIIC (unresectable/not suitable for radiotherapy) or Stage IV NSCLC without EGFR or ALK mutations, at least one measurable tumor, ECOG performance status 0-1, life expectancy over 3 months, adequate organ function, and negative pregnancy test for women of child-bearing potential.

The treatments include paclitaxel, pembrolizumab, pemetrexed, and carboplatin administered as intravenous infusions. BNT327 is an investigational medication being tested for effectiveness, while pembrolizumab is already used for cancer treatment. The study monitors disease progression, overall survival, and treatment side effects over time.

Study on THIO and Cemiplimab for Patients with Advanced Non-Small Cell Lung Cancer

This trial in Poland, Romania, Hungary, and Bulgaria evaluates THIO (a specially designed chemical compound) and cemiplimab (LIBTAYO®, a protein-based medication) for advanced NSCLC. Patients must be at least 18 years old, agree to use effective birth control, provide written informed consent, have advanced NSCLC (Stage 3 or 4) that worsened or returned after previous treatment including anti-PD-1/PD-L1, have only received one previous treatment for advanced NSCLC, have at least one measurable cancer area, provide tumor tissue sample if available, have ECOG performance status 0-1, and have adequate organ function.

The treatments are given as intravenous infusions in a specific sequence. The goal is to assess safety, tolerability, and effectiveness by monitoring cancer response and side effects. Both THIO and cemiplimab are administered through intravenous infusion. Cemiplimab works by blocking the PD-1 pathway to help the immune system attack cancer cells.

Study on Tiragolumab and Atezolizumab for Patients with Resected Stage IIB-IIIB Non-Small Cell Lung Cancer After Chemotherapy

This trial across Slovakia, Italy, France, Austria, Greece, Germany, Poland, Hungary, Romania, Ireland, Belgium, and Spain tests tiragolumab combined with atezolizumab versus placebo with atezolizumab for patients who underwent surgery and received chemotherapy. The study aims to prevent cancer recurrence in patients whose tumors have PD-L1 protein.

Eligible patients must have NSCLC diagnosis, ECOG performance status 0-1, confirmed Stage IIB, IIIA, or certain Stage IIIB NSCLC, complete tumor removal, mediastinal lymph node systematic sampling, received 1-4 cycles of adjuvant platinum doublet chemotherapy, recovered well from surgery and chemotherapy with no severe ongoing side effects. Both males and females can participate, and participants should not be from vulnerable populations.

Both medications are administered through intravenous infusion. Tiragolumab is investigational, enhancing immune response by targeting TIGIT protein, while atezolizumab blocks PD-L1 protein to help immune system recognition of cancer cells. The treatment period can last up to 12 months, with regular monitoring for side effects and cancer status.

Study on Tislelizumab and Chemotherapy for Patients with Stage III PD-L1 Positive Non-Small Cell Lung Cancer

This Italian trial evaluates tislelizumab combined with platinum-based doublet chemotherapy for stage III PD-L1 positive NSCLC. The chemotherapy drugs include pemetrexed, cisplatin, carboplatin, and paclitaxel, all administered intravenously. The treatment is given before surgery to prepare patients and aims to achieve complete tumor removal.

Eligible patients must have confirmed stage III disease, be at least 18 years old, provide written consent, have PD-L1 TPS 1% or higher, no EGFR/ALK/ROS1/RET mutations, baseline multidisciplinary assessment confirming suitability for curative treatment, pulmonary function tests within 6 months, at least one measurable lesion, ECOG Performance Status 0-1, eligibility for platinum doublet chemotherapy, and adequate organ function.

Tislelizumab is administered as an intravenous infusion and works by blocking PD-1 protein on immune cells, helping the immune system recognize and attack cancer cells. The platinum-based chemotherapy damages cancer cell DNA to stop growth and division, aiming to shrink tumors before surgery.

Summary

These 27 ongoing clinical trials represent significant research efforts to improve treatment outcomes for patients with non-small cell lung cancer stage III. The trials are concentrated primarily in Western European countries, with France, Germany, Italy, Spain, and Poland hosting the largest number of studies. This geographic distribution reflects both the established clinical trial infrastructure in these countries and the significant patient populations affected by this disease.

A notable pattern across these trials is the prominent focus on immunotherapy approaches, particularly drugs targeting the PD-1/PD-L1 pathway. Durvalumab appears in multiple trials, often as a maintenance therapy following chemoradiotherapy or in combination with surgery. Other immunotherapy agents being investigated include atezolizumab, pembrolizumab, tislelizumab, and cemiplimab. This emphasis on immunotherapy reflects the evolving standard of care for stage III NSCLC, where immune checkpoint inhibitors have shown promise in extending disease-free survival.

Several trials are exploring targeted therapies for specific genetic mutations, including sotorasib for KRAS G12C-mutated tumors, osimertinib for EGFR-mutated cancers, and alectinib for ALK-positive disease. This personalized medicine approach recognizes that stage III NSCLC is not a single disease but encompasses multiple molecular subtypes requiring tailored treatment strategies.

Many studies are investigating combination approaches, testing whether adding immunotherapy to standard chemotherapy and radiation therapy, or combining multiple immunotherapy agents, can improve outcomes. The trials also explore different treatment sequences, including neoadjuvant therapy before surgery and adjuvant therapy afterward, attempting to optimize the timing and combination of treatments.

Patient eligibility criteria across trials typically require good performance status, adequate organ function, and specific molecular characteristics of tumors. This reflects the complexity of treating stage III disease and the need to identify patients most likely to benefit from these intensive treatment approaches while minimizing risks of serious side effects.

Ongoing Clinical Trials on Non-small cell lung cancer stage II

  • Study of cemiplimab treatment after surgery in patients with stage II-IIIA non-small cell lung cancer who have not received chemotherapy and have PD-L1 expression of 1% or higher

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Estonia France Germany Ireland Italy +1

  • Testing MK-2870 with pembrolizumab compared to pembrolizumab alone after surgery in patients with non-small cell lung cancer who did not respond fully to treatment

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Czechia France Germany Greece +7

  • Study of IPH5201 and Durvalumab for Pre- and Post-Surgery Treatment in Patients with Early-Stage Non-Small Cell Lung Cancer

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    France Greece Hungary Poland

  • Study on the Effects of Adding Durvalumab After Chemotherapy and Surgery in Patients with Resectable Non-Small Cell Lung Cancer

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Estonia France Ireland Italy +1

  • Study of Volrustomig and Drug Combination for Patients with Early-stage Resectable Non-small Cell Lung Cancer

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium France Hungary Ireland Italy Portugal +1

  • Study of sacituzumab govitecan and zimberelimab treatment before and after surgery for patients with resectable non-small cell lung cancer

    Not yet recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany

  • Study on Tiragolumab and Atezolizumab for Patients with Resected Stage IIB-IIIB Non-Small Cell Lung Cancer After Chemotherapy

    Not recruiting

    1 1 1
    Investigated diseases:
    Austria Belgium France Germany Greece Hungary +6

  • Study on the Effectiveness and Safety of Osimertinib for Patients with Stage IB-IIIA Non-Small Cell Lung Cancer After Tumor Removal

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium France Germany Italy Poland Spain +1

More information about
Non-small cell lung cancer stage II:

Connected medications: